Aitiologic
A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment.
€6.4MSeed
ParticipantDG
Dr. Gordon Sanghera CBE FRS
Activity from announced rounds
Activity in this selectionkorea-investment-partners-dbedb086
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $7.4M 1 disclosed · full round size, not this investor’s share